Tech Company Financing Transactions
Memo Therapeutics Funding Round
Adjuvant Capital, Fresenius Medical Care and GF Private Equity Group participated in a $22 million Series C capital raise for Memo Therapeutics. The financing round was announced by the company on 5/7/2024.
Transaction Overview
Company Name
Announced On
5/7/2024
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to bolster the clinical advancement of its lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Wagistrasse 27
Schlieren / Zurich, 8952
Switzerland
Schlieren / Zurich, 8952
Switzerland
Phone
Website
Email Address
Overview
Memo Therapeutics AG ("MTx") is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx' lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. AntiBKV has successfully completed Phase I with no safety concerns, with Phase II (POC) data expected in H1 2025. MTx' pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus ("CMV"), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Elias Papatheodorou
Chief Executive Officer
Erik Van Den Berg
Chief Financial Officer
Lars Spenger
Chief Marketing Officer
Jürgen Beck
Chief Scientific Officer
Christoph Esslinger
Vice President
Maartje Verschuur
VP - Bus. Development
Gerald Parzmair
VP - Operations
Kristie Clemmer
VP - Operations
Simone Schmitt
Browse more venture capital transactions:
Prev: 5/7/2024: Acclinate venture capital transaction
Next: 5/7/2024: Inkbit venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs